

ICMJE DISCLOSURE FORM

Date: 07/aug/2023

Your Name: Mahira de Oliveira Lopes da Rosa

Manuscript Title: "Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives"

Manuscript number (if known): TBCR 23-43

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	__X__	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__X	
3	Royalties or licenses	__X__	
4	Consulting fees	__X__	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> X </u>	
6	Payment for expert testimony	<u> X </u>	
7	Support for attending meetings and/or travel	<u> X </u>	
8	Patents planned, issued or pending	<u> X </u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> X </u>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u>	
11	Stock or stock options	<u> X </u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u>	
13	Other financial or non-financial interests	<u> X </u>	

Please summarize the above conflict of interest in the following box:

NONE

Please place an "X" next to the following statement to indicate your agreement:

(x) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Aug 06, 2023

Your Name: Tomas Reinert

Manuscript Title: Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives

Manuscript number (if known): TBCR 23-43

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	__X__	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__	
3	Royalties or licenses	__X__	
4	Consulting fees	AstraZeneca, Lilly, MSD and Novartis.	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Daiichi-Sankyo, AstraZeneca, Gilead Libbs, Pfizer, MSD and Novartis	
6	Payment for expert testimony	<u> X </u>	
7	Support for attending meetings and/or travel	<u> X </u>	
8	Patents planned, issued or pending	<u> X </u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	AstraZeneca, Lilly, MSD and Novartis.	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u>	
11	Stock or stock options	<u> X </u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u>	
13	Other financial or non-financial interests	<u> X </u>	

Please summarize the above conflict of interest in the following box:

Speaker's honoraria from Daiichi-Sankyo, AstraZeneca, Gilead Libbs, Pfizer, MSD and Novartis. Consulting fees for advisory boards from AstraZeneca, Lilly, MSD and Novartis. Research funding from AstraZeneca, FAPESP, Libbs, PRONOM/MS.

Please place an "X" next to the following statement to indicate your agreement:

(x) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

tomas reinert

Tomas Reinert

ICMJE DISCLOSURE FORM

Date: August 06, 2023

Your Name: Maiane Maria Pauletto

Manuscript Title: Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives

Manuscript number (if known): TBCR 23-43

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	X	
3	Royalties or licenses	X	
4	Consulting fees	X	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X	
6	Payment for expert testimony	X	
7	Support for attending meetings and/or travel	X	
8	Patents planned, issued or pending	X	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X	
11	Stock or stock options	X	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X	
13	Other financial or non-financial interests	X	

Please summarize the above conflict of interest in the following box:

NONE

Please place an "X" next to the following statement to indicate your agreement:

(X) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Maiane Pavesio

ICMJE DISCLOSURE FORM

Date: August, 6th, 2023

Your Name: Guilherme Parisotto Sartori

Manuscript Title: Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives

Manuscript number (if known): TBCR 23-43


In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u> X </u>	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u> X </u>	
3	Royalties or licenses	<u> X </u>	
4	Consulting fees	<u> X </u>	



5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Astrazeneca	
		Novartis	
		Daichi-Sankyo	
6	Payment for expert testimony	<u> X </u>	
7	Support for attending meetings and/or travel	Astrazeneca	
8	Patents planned, issued or pending	<u> X </u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Astrazeneca	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u>	
11	Stock or stock options	<u> X </u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u>	
13	Other financial or non-financial interests	<u> X </u>	

Please summarize the above conflict of interest in the following box:

Daichi-Sankyo: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing). AstraZeneca: Consulting Fees (e.g., advisory boards) and Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing). Novartis: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus) (Ongoing).

Please place an "X" next to the following statement to indicate your agreement:

(X) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Aug 06, 2023

Your Name: MARCIA SILVEIRA GRAUDENZ

Manuscript Title: Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives

Manuscript number (if known): TBCR 23-43

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	__X__	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	__X__	
3	Royalties or licenses	__X__	
4	Consulting fees	AstraZeneca and Novartis	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Daiichi-Sankyo, AstraZeneca and Novartis	
6	Payment for expert testimony	<u> X </u>	
7	Support for attending meetings and/or travel	<u> X </u>	
8	Patents planned, issued or pending	<u> X </u>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> X </u>	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> X </u>	
11	Stock or stock options	<u> X </u>	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> X </u>	
13	Other financial or non-financial interests	<u> X </u>	

Please summarize the above conflict of interest in the following box:

MSG has received speaker's honoraria from Daiichi-Sankyo, AstraZeneca and Novartis. Consulting fees for advisory boards from AstraZeneca and Novartis. Research funding from AstraZeneca and Libbs

Please place an "X" next to the following statement to indicate your agreement:

(X) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: August 6th 2023

Your Name: Carlos H Barrios

Manuscript Title: Implications of tumor-infiltrating lymphocytes (TILs) in early-stage triple-negative breast cancer: clinical oncologist perspectives

Manuscript number (if known): TBCR 23-43

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	(to the institution) Nektar, Pfizer, Polyphor, Amgen, Daiichi Sankyo, Sanofi, Exelixis, Regeneron, Novartis, GSK, Janssen, OBI Pharma, Lilly, Seagen, Roche, BMS, MSD, Merck Serono, Astra Zeneca,	

		Novocure, Aveo Oncology, Takeda, TRIO, PharmaMar, Celgene, PPD, Syneos Health, Labcorp, ICON, IQVIA, Parexel, Nuvisan, PSI, Worldwide, Gilead Sciences, Bayer, Servier.	
3	Royalties or licenses	x	
4	Consulting fees	Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiich	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiich	
6	Payment for expert testimony	x	
7	Support for attending meetings and/or travel	Novartis, Pfizer, Roche/Genentech, MSD, Astra Zeneca, Lilly, Daiich	
8	Patents planned, issued or pending	x	
9	Participation on a Data Safety Monitoring Board or Advisory Board	ROCHE	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	x	
11	Stock or stock options	Thummi, MEDSIR	
12	Receipt of equipment, materials, drugs, medical	x	

	writing, gifts or other services		
13	Other financial or non-financial interests	X	

Please summarize the above conflict of interest in the following box:

CHB has received grants or contracts to the institution from Nektar, Pfizer, Polyphor, Amgen, Daiichi Sankyo, Sanofi, Exelixis, Regeneron, Novartis, GSK, Janssen, OBI Pharma, Lilly, Seagen, Roche, BMS, MSD, Merck Serono, Astra Zeneca, Novocure, Aveo Oncology, Takeda, TRIO, PharmaMar, Celgene, PPD, Syneos Health, Labcorp, ICON, IQVIA, Parexel, Nuvisan, PSI, Worldwide, Gilead Sciences, Bayer, Servier. Consulting fees from Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiichi. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi, Daiichi. Support for attending meetings and/or travel from Novartis, Pfizer, Roche/Genentech, MSD, Astra Zeneca, Lilly, Daiichi. Participation on a Data Safety Monitoring Board or Advisory Board from Roche. Stock from Thummi and MEDSIR.

Please place an "X" next to the following statement to indicate your agreement:

(X) I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Carlos H Barrios MD
 Medical Oncologist
 LACOG